Key result
This review highlights the interplay of TGF-β and BMPR2 signaling in pulmonary arterial hypertension, emphasizing their roles in vascular remodeling and potential as therapeutic targets.
This review highlights the interconnected roles of TGF-β and BMPR2 signaling in PAH pathogenesis and discusses potential therapeutic targets within these pathways.
Does not alter current PAH management; leaves open whether TGF-β/BMPR2 modulation improves outcomes.
Knowledge pertaining to the involvement of transforming growth factor β (TGF-β) and bone morphogenetic protein (BMP) signaling in pulmonary arterial hypertension (PAH) is continuously increasing. There is a growing understanding of the function of individual components involved in the pathway, but a clear synthesis of how these interact in PAH is currently lacking. Most of the focus has been on signaling downstream of BMPR2, but it is imperative to include the role of TGF-β signaling in PAH. This review gives a state of the art overview of disturbed signaling through the receptors of the TGF-β family with respect to vascular remodeling and cardiac effects as observed in PAH. Recent (pre)-clinical studies in which these two pathways were targeted will be discussed with an extended view on cardiovascular research fields outside of PAH, indicating novel future perspectives.
No takes yet. Share an insight, caveat, or question.
Rol et al. (2018) conducted a review in Pulmonary arterial hypertension (PAH). TGF-β and BMPR2 signaling pathways was evaluated. This review highlights the interplay of TGF-β and BMPR2 signaling in pulmonary arterial hypertension, emphasizing their roles in vascular remodeling and potential as therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: